Explore
Validate
Learn17868-1-AP
antibody from Proteintech Group
Targeting: CYP2D6
CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, P450-DB1, P450C2D
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [10]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17868-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- CYP2D6/7 antibody
- Antibody type
- Polyclonal
- Description
- CYP2D6/7 antibody (Cat. #17868-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Integrated pharmacokinetic properties, tissue distribution and metabolism of multiple active constituents in DBD for the treatment of GEM-induced myelosuppression.
Genome edited intestine liver on a chip system for integrated intestinal hepatic drug absorption and metabolism evaluation.
Refining Hepatocyte Models to Capture the Impact of CYP2D6*10 Utilizing a PITCh System.
Comparison of mouse and human cytochrome P450 mediated-drug metabolising activities in hepatic and extrahepatic microsomes.
Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug.
Cloning, sequence analysis, and tissue expression of marmoset paraoxonase 1.
Effects of Saikosaponin D on CYP1A2 and CYP2D6 in HepaRG Cells.
Silybin enhances the blood concentration of brexpiprazole in rats by downregulating expression of CYP3A4 and CYP2D6.
Generation of hepatic spheroids using human hepatocyte-derived liver progenitor-like cells for hepatotoxicity screening.
CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance.
Qi X, Zuo L, Chen C, Zhang Y, Zhang P, Han M, Liu D, Ni M, Jia Q, Liu Y
Journal of ethnopharmacology 2026 Mar 25;359:121084
Journal of ethnopharmacology 2026 Mar 25;359:121084
Genome edited intestine liver on a chip system for integrated intestinal hepatic drug absorption and metabolism evaluation.
Negoro R, Deguchi S, Yamazaki D, Takayama K, Fujita T
Scientific reports 2025 Nov 4;15(1):38609
Scientific reports 2025 Nov 4;15(1):38609
Refining Hepatocyte Models to Capture the Impact of CYP2D6*10 Utilizing a PITCh System.
Negoro R, Ouchi A, Deguchi S, Takayama K, Fujita T
Biological & pharmaceutical bulletin 2024;47(8):1422-1428
Biological & pharmaceutical bulletin 2024;47(8):1422-1428
Comparison of mouse and human cytochrome P450 mediated-drug metabolising activities in hepatic and extrahepatic microsomes.
Uehara S, Murayama N, Higuchi Y, Yoneda N, Yamazaki H, Suemizu H
Xenobiotica; the fate of foreign compounds in biological systems 2022 Mar;52(3):229-239
Xenobiotica; the fate of foreign compounds in biological systems 2022 Mar;52(3):229-239
Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug.
Guo J, Xu Y, Chen LJ, Zhang SX, Liou YL, Chen XP, Tan ZR, Zhou HH, Zhang W, Chen Y
Journal of advanced research 2022 Jul;39:319-332
Journal of advanced research 2022 Jul;39:319-332
Cloning, sequence analysis, and tissue expression of marmoset paraoxonase 1.
Uehara S, Uno Y, Shimizu M, Yamazaki H
Drug metabolism and pharmacokinetics 2021 Aug;39:100398
Drug metabolism and pharmacokinetics 2021 Aug;39:100398
Effects of Saikosaponin D on CYP1A2 and CYP2D6 in HepaRG Cells.
Li H, Tang Y, Wang Y, Wei W, Yin C, Tang F
Drug design, development and therapy 2020;14:5251-5258
Drug design, development and therapy 2020;14:5251-5258
Silybin enhances the blood concentration of brexpiprazole in rats by downregulating expression of CYP3A4 and CYP2D6.
Yu C, Pan L, Wang G, Cai Z, Zhou Y, Zheng X, Chen C, Zhang X
Die Pharmazie 2020 May 1;75(5):198-200
Die Pharmazie 2020 May 1;75(5):198-200
Generation of hepatic spheroids using human hepatocyte-derived liver progenitor-like cells for hepatotoxicity screening.
Wang Z, Li W, Jing H, Ding M, Fu G, Yuan T, Huang W, Dai M, Tang D, Zeng M, Chen Y, Zhang H, Zhu X, Peng Y, Li Q, Yu WF, Yan HX, Zhai B
Theranostics 2019;9(22):6690-6705
Theranostics 2019;9(22):6690-6705
CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance.
Sonawane VR, Siddique MUM, Gatchie L, Williams IS, Bharate SB, Jayaprakash V, Sinha BN, Chaudhuri B
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2019 Apr 1;131:177-194
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2019 Apr 1;131:177-194
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- mouse liver tissue were subjected to SDS PAGE followed by western blot with 17868-1-AP( CYP2D6 Antibody) at dilution of 1:300
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The CYP2D6 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human CYP2D6. This antibody recognizes human,mouse,rat antigen. The CYP2D6 antibody has been validated for the following applications: ELISA, IHC, WB analysis.
